LivaNova has announced it has acquired the remaining outstanding interests in Caisson Interventional in support of its strategic growth initiatives. Based in Maple Grove (USA), Caisson is a privately held clinical-stage medical device company focused on the design, development and clinical evaluation of a novel transcatheter mitral valve implantation (TMVI) implant with a fully transvenous delivery system.
A press release reports that Caisson’s device is unique, being the only TMVI product designed solely for trans-septal approach and delivered through a single venous access. The system is also designed for the implant to be fully retrieved following functional evaluation, but prior to final release—a safety feature important to physicians.
LivaNova’s CEO Damien McDonald comments: “We recognised the potential of the talented Caisson team and its technology several years ago. This team will now be the cornerstone for our planned entry into the TMVI space, which has the potential to be an important growth platform for us in the future. We intend to invest in the clinical studies, regulatory approvals, product enhancements and other steps needed to launch this mitral valve replacement system commercially. We expect it will become a strategic complement to our heart valve portfolio for heart team physicians, allowing us to offer patients the most advanced, minimally invasive mitral valve replacement option.”
Caisson initiated its clinical trials through the US FDA Early Feasibility Study program, and will add clinical sites in Europe and Canada.
